Public Equity Report: Signs of life for biotech IPOs as Zenas, Bicara file, TYK sticks landing

It’s been an underwhelming year for biotech IPOs, but a pair of companies fresh off nine-digit crossover rounds have set their sights on NASDAQ-listings — even amid the uncertainty of the looming election in the U.S. and a year of generally lousy after-market moves for newly public companies — and one company from China got out in Hong Kong. 

Three months after raising a $200 series C round led by SR One, New Enterprise Associates, Norwest Venture Partners and Delos Capital, Lonnie Moulder’s Zenas BioPharma Inc. filed to go public under the ticker “ZBIO.” Moulder, Zenas’ founder, was a co-founder and former CEO of Tesaro Inc., which GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) acquired for $5.1 billion...